

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ya Fang LIU

Art Unit: 1645

Serial No.: 09/156,367

Examiner: Marianne P. Allen

Filed: September 17, 1998

For: A Method for Identifying  
MLK Inhibitors for Treatment of  
Neurological Conditions

Attorney Docket No.: 109062.114

RECEIVED  
COMM CENTER 1600/2900  
00 MAY -8 PM 2:31

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail with sufficient postage in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

\_\_\_\_\_  
Date of Signature and of Mail Deposit

By \_\_\_\_\_  
Deborah Gagen

**DECLARATION UNDER 37 C.F.R. § 1.132  
(In Re Katz Declaration)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

I, Ya Fang Liu, M.D., Ph.D., declare the following:

1. I am the applicant of the above-identified patent application and inventor of the subject matter described and claimed therein.
2. I am the sole inventor of the subject matter described and claimed in this application for the methods directed to targeting activated JNK activity or activated MLK activity in neuronal cells with a compound to determine that compound's ability to prevent neuronal cell death.

3. I am one of six named authors for the abstract "Expression of the Huntingtin Mutant Activates JNK/SAPK and Induces Neuronal Apoptosis," published in *Society for Neuroscience*, vol. 23, 1997.

4. None of the other named authors were involved in conducting or performing any experiments described in this abstract. Further, I did not receive any financial support for the experiments described in this abstract.

5. Hemachandra Reddy, Danilo A. Tagle, and P. Lisa Pike Buchanan were named as authors for supplying me with the full-length huntingtin constructs that were used in my experiments. While they were named as authors on this abstract, they did not contribute to the conception of the claimed invention, that is, methods directed to targeting activated JNK activity or activated MLK activity in neuronal cells with a compound to determine that compound's ability to prevent neuronal cell death based on the discovery that the over-activation or stimulation of the MLK-SEK1-JNK cascade leads to the increase of expression, activation and translocation of c-Jun which is responsible for neuronal cell death in neurodegenerative disorders. For that reason, they are not named as co-inventors on the patent application.

6. Leny Zon was named as an author on the abstract for supplying me with wild-type and dominant negative mutants of SEK1 that were used in my experiments. While he was named as an author, he did not contribute to the conception of the invention.

7. Rechard Deth was named as an author on the abstract for his overall support of my research efforts. While he was named as an author, he did not contribute to the conception of the invention.


8. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that the statements were made with the knowledge that wilful false

Declaration Under 37 C.F.R. § 1.132  
Serial No. 09/156,367

statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issuing thereon.

Further, declarant saith not.

4/6/2000  
Date

  
Ya Fang Liu M.D., Ph.D.

hollie baker - z:\legal\liu\109062.114\in\_re\_katz\_declaration\_2.doc